USE OF GANODERMA FUNGAL RNA MOLECULES, DRUG, DRUG COMPOSITION AND DELIVERY CARRIER
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Jan 16, 2025
app pub date -
Nov 17, 2022
filing date -
Nov 17, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
A use of ganoderma fungal RNA molecules, a drug, a drug composition and a delivery carrier are provided. It has been proved that the tRFs derived from the ganoderma traditional Chinese medicine has an obvious inhibiting effect on airway smooth muscle cell phenotype change (proliferation, abnormal secretion and the like) induced by TGF-β1 and AHR, inflammation and remodeling of asthma mice induced by Dermatophagoides pteronyssinus in the experiments of the present disclosure, which suggests that the tRFs derived from the ganoderma traditional Chinese medicine and a pharmaceutical composition can be a brand new medicine for treating asthma. The drug comprises the RNA molecule and a pharmaceutically acceptable carrier, diluent and/or excipient. The present disclosure is helpful for the research and development of asthma treatment drugs and provides reference for the research and development of other respiratory system disease treatment drugs.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully